Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ifebemtinib combinations in advanced pancreatic cancer
NCT05827796Phase 2Recruiting
- Sponsor
- InxMed
- Start
- Dec 2022
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ifebemtinib in pancreatic ductal adenocarcinoma (PDAC), sponsored by InxMed. Started Dec 2022; status: recruiting.
02
Drugs
ifebemtinib
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05827796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05827796.